Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0948008
Disease: Ischemic stroke
Ischemic stroke
0.100 Biomarker disease BEFREE Cytoprotective APC therapy holds promise for the treatment of ischemic stroke, and a recently completed trial suggested that cytoprotective-selective 3K3A-APC reduced bleeding in ischemic stroke patients. 31348046 2019
CUI: C0948008
Disease: Ischemic stroke
Ischemic stroke
0.100 Biomarker disease BEFREE Thrombin aggravates ischemic stroke and activated protein C (APC) has a neuroprotective effect. 30718498 2019
CUI: C0948008
Disease: Ischemic stroke
Ischemic stroke
0.100 Biomarker disease BEFREE Analogs of activated protein C (APC) exert pleiotropic anti-inflammatory, anti-apoptotic, antithrombotic, cytoprotective, and neuroregenerative effects in ischemic stroke and thus appear to be promising candidates for this novel approach. 28923278 2018
CUI: C0948008
Disease: Ischemic stroke
Ischemic stroke
0.100 GeneticVariation disease BEFREE Using these strains, we determined whether or not recombinant murine signaling-selective APC mutants would reduce septic death or provide neuroprotection against ischemic stroke when mice carried PAR1-homozygous mutations that prevent cleavage at either R41 or R46. 29343482 2018
CUI: C0948008
Disease: Ischemic stroke
Ischemic stroke
0.100 Biomarker disease BEFREE These recent advances should encourage translational research centered on signaling selective APC's for both single-agent therapies and multiagent combination therapies for ischemic stroke and other neuropathologies. 29866816 2018
CUI: C0948008
Disease: Ischemic stroke
Ischemic stroke
0.100 Biomarker disease BEFREE Collectively, this study reveals the importance of APC glycosylation in controlling the efficacy of PAR1 proteolysis by APC and demonstrates the potential of novel APC variants with superior cytoprotective signaling function as enhanced therapeutic agents for the treatment of ischemic stroke. 26084674 2015
CUI: C0948008
Disease: Ischemic stroke
Ischemic stroke
0.100 Biomarker disease BEFREE The cytoprotective effects are protease activated receptor 1 (PAR-1) and endothelial protein C receptor (EPCR) dependent and likely underlie protective effects of APC in animal models of sepsis, myocardial infarction and ischemic stroke. 25032959 2014
CUI: C0948008
Disease: Ischemic stroke
Ischemic stroke
0.100 Biomarker disease BEFREE Remarkably, pharmacologic therapy using APC demonstrates substantial neuroprotective effects in various murine injury models, including ischemic stroke. 22477541 2012
CUI: C0948008
Disease: Ischemic stroke
Ischemic stroke
0.100 Biomarker disease BEFREE In mice, treatment of experimental ischemic stroke with activated protein C improves outcomes; however, activated protein C also has bleeding side effects. 21512172 2011
CUI: C0948008
Disease: Ischemic stroke
Ischemic stroke
0.100 Biomarker disease BEFREE Thus, 3K3A-APC exhibits species-dependent neuroprotection which should be taken into account when designing human trials for ischemic stroke with APC mutants. 19166505 2009
CUI: C0948008
Disease: Ischemic stroke
Ischemic stroke
0.100 Biomarker disease BEFREE Drotrecogin-alfa activated, a hyperanticoagulant form of human recombinant APC, is currently being studied in patients with ischemic stroke. 19057019 2009